Spectral Medical Inc. provided an update on the Company's Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion ("PMX") in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continues throughout 2024: 88 patients enrolled to-date; Six patients enrolled in the month of January, which is the higher monthly enrollment experienced since the start of the Tigris study; One patient enrolled in February to date; Closing in on the interim enrollment target of 90 patients ("Interim Enrollment"); at Interim Enrollment, Baxter has the option to make the second milestone payment to Spectral to maintain its PMX exclusive distribution rights. Trial Sites: Continue to make progress opening an additional six new, high quality clinical sites.

University of Texas Health Sciences Center at Houston finalized and executed the Tigris clinical trial agreement; the Company anticipates another Texas-based site to execute its clinical trial agreement in the coming days; expect significant site onboarding activity in First Quarter/24, with final training scheduled at four sites in February so far.